- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05941845
Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy (ALPHAGEM)
Study of Immunological Activity After Personalized Immunomodulatory Therapy Regulating the Th17 Pathway in Patients With Membranous Nephropathy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Maxime TEISSEYRE, MD
- Phone Number: +33492038828
- Email: teisseyre.m@chu-nice.fr
Study Contact Backup
- Name: Céline FERNANDEZ, MsC
- Phone Number: +33492038828
- Email: fernandez.c3@chu-nice.fr
Study Locations
-
-
-
Nice, France
- CHU de Nice
-
Contact:
- Céline FERNANDEZ
- Phone Number: +33492038828
- Email: fernandez.c3@chu-nice.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 and above
- Diagnosis of membranous nephropathy PLA2R1 antibodies-mediated
- Immunological relapse (defined as an increase in anti-PLA2R1 antibody titer > 14 RU/mL after a phase of anti-PLA2R1 antibody negativation, i.e. immunological remission)
- Plasma IL-17A levels > 73 pg/mL after non-specific stimulation of peripheral blood immune cells
- Symptomatic anti-proteinuric treatment at a stable, maximum-tolerated dosage;
- Patients with: (i) a platelet count≥ 90,000 cells/mm3; (ii) a neutrophil count ≥ 1500 cells/mm3; and (iii) appropriately monitored normal thyroid function (TSH and T4) at screening
Exclusion Criteria:
- Immunosuppressive treatment for MN in the 6 months before screening
- Secondary MN (associated with cancer, infectious disease, autoimmune or iatrogenic disease)
- Active nephrotic syndrome defined according to KDIGO guidelines by proteinuria > 3.5 g/day (or 3.5 g/g urine sample) and albuminemia < 30 g/L
- Absence of previous immunological (anti-PLA2R1 antibodies < 14 RU/mL in ELISA or negative indirect immunofluorescence) and clinical (partial or complete) remission
- Patients with a history of thrombosis or treated with anticoagulants
- Pregnancy or breastfeeding
- Cancer in treatment
- Pre-existing retinopathy
- Active and severe infections
- Severe liver failure or cirrhosis
- Pre-existing severe heart failure
- Pre-existing psychiatric disorder or patient at risk of anxiety or depression (HAD Score > 11)
- Patients who use or abuse substances
- Hypersensitivity to active substance or excipients of study treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 6-month interferon alfa treatment
|
Injections will be carried out on the Nephrology day hospitalization ward. The injections follows a personalized administration schedule: all enrolled patients will receive an injection of Pegasys® at Week 0. Patients with a persistent Th17 profile (cytokine profile showing IL-17A levels greater than 73 pg/ml) at Week 2 will receive a new dose of Pegasys®, followed by a monthly cytokine profile. In the case of a persistent Th17 profile, 2 injections will be given two weeks apart. In patients with no Th17 profile at Week 2, no Pegasys® injections will be performed at this time. Cytokine profiles will be performed monthly, and in the case of a persistent Th17 profile, 1 injection will be performed. In total, patients will receive a minimum of one injection and a maximum of 13 injections of 180 µg (1 injection every two weeks for 24 weeks).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Membranous nephropathy immunological activity monitoring over 6-month interferon alfa treatment
Time Frame: 18 months
|
Intra-individual variation in anti-PLA2R1 antibody titer (ELISA titer in RU/mL), before and after 6 months of treatment with IFN alfa
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nephrotic syndrome monitoring over 6-month interferon alfa treatment
Time Frame: Baseline to Week 24
|
Intra-individual variation in proteinuria (g/g) under IFN alfa and stable symptomatic treatment
|
Baseline to Week 24
|
Nephrotic syndrome monitoring over 6-month interferon alfa treatment
Time Frame: Baseline to Week 24
|
Intra-individual variation in albuminemia (g/L) under IFN alfa and stable symptomatic treatment
|
Baseline to Week 24
|
Immune response monitoring over 6-month interferon alfa treatment
Time Frame: Baseline to Week 24
|
Intra-individual variation in cytokine profile (assay of 8 cytokines in pg/ml: IL-12p70; IL-17A; IL-4; IL-5; IL-1β; IL-10; IFNα; IL-6) before and after 6 months of personalized treatment with IFN alfa
|
Baseline to Week 24
|
Immune response monitoring over 6-month interferon alfa treatment
Time Frame: Baseline to Week 24
|
Intra-individual variation in cytokine profile (assay of 1 cytokine in UI/ml: IFNγ) before and after 6 months of personalized treatment with IFN alfa
|
Baseline to Week 24
|
Clinical Tolerance monitoring over 6-month interferon alfa treatment
Time Frame: At Week 52
|
Percentage of Participants with clinical Adverse Events (AEs)
|
At Week 52
|
Biological Tolerance monitoring over 6-month interferon alfa treatment
Time Frame: At Week 52
|
Percentage of Participants with biological Adverse Events (AEs)
|
At Week 52
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Urologic Diseases
- Nephritis
- Glomerulonephritis
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Glomerulonephritis, Membranous
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Immunologic Factors
- Interferons
- Interferon-alpha
- Peginterferon alfa-2a
Other Study ID Numbers
- 22-AOIP-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Membranous Nephropathy
-
Hospital Universitario 12 de OctubreInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz; Fundación... and other collaboratorsCompletedMEMBRANOUS NEPHROPATHYSpain
-
Beijing Friendship HospitalRecruitingIdiopathic Membranous NephropathyChina
-
Qianfoshan HospitalNot yet recruitingIdiopathic Membranous Nephropathy
-
Qianfoshan HospitalNot yet recruitingIdiopathic Membranous Nephropathy
-
Peking Union Medical College HospitalBeijing Tongren Hospital; Shanghai Fosun Pharmaceutical Industrial Development... and other collaboratorsRecruitingIdiopathic Membranous NephropathyChina
-
wanglinCompletedIdiopathic Membranous NephropathyChina
-
Manchester University NHS Foundation TrustFresenius AGCompletedAutoimmune Membranous NephropathyUnited Kingdom
-
Guangdong Provincial People's HospitalTerminatedIdiopathic Membranous NephropathyChina
-
Xinhua Hospital, Shanghai Jiao Tong University...UnknownIdiopathic Membranous NephropathyChina
-
Qianfoshan HospitalNot yet recruitingIdiopathic Membranous Nephropathy
Clinical Trials on Peginterferon Alfa-2A 180 MCG/ML Injectable Solution
-
PharmaEssentiaCompleted
-
National Taiwan University HospitalNational Science Council, TaiwanUnknownHepatitis B, ChronicTaiwan
-
The Wistar InstituteNational Institute of Allergy and Infectious Diseases (NIAID); Hoffmann-La... and other collaboratorsCompleted
-
Hoffmann-La RocheCompleted
-
National Taiwan University HospitalNational Science Council, TaiwanUnknownHepatitis B, ChronicTaiwan
-
Columbia UniversityMerck Sharp & Dohme LLCWithdrawnEnd Stage Renal Disease | Hepatitis C Infection
-
PharmaEssentiaCompleted
-
Germans Trias i Pujol HospitalFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...CompletedHIV Infections | Hepatitis CSpain
-
Instituto Nacional de Cardiologia Ignacio ChavezUnknownCoronary Artery DiseaseMexico
-
Tufts Medical CenterDompé Farmaceutici S.p.AWithdrawn